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Editorial
DREAM Study and Its Impact on India
V Mohan*
Pre-diabetes denotes a stage prior to clinical onset ofdiabetes. This includes two conditions namely
Impaired Glucose Tolerance (IGT) and Impaired Fasting
Glucose (IFG).1,2 Over one third of subjects with pre-
diabetes develop diabetes within five years.3 Individuals
with pre-diabetes are not only at high risk for developing
diabetes but are also considered to be at increased risk
for coronary artery disease.3-5
Although lifestyle modification i.e diet, physical
activity and weight loss have been clearly shown to
prevent diabetes in people with pre-diabetes in several
large studies like the Diabetes Prevention Program [DPP]6
and Diabetes Prevention Study [DPS],7 additional
strategies for high-risk individuals are urgently needed.
Moreover application of these trials to real life is very
difficult as people are not always willing for lifestyle
modification.  In this context, the recent Diabetes
REduction Assessment with ramipril and rosiglitazone
Medication [DREAM] trial results8,9 have great
implications, particularly in Indians owing to the high
risk for diabetes and cardiovascular disease.
DREAM [Diabetes Reduction Assessment with
ramipril and rosiglitazone Medication] Trial
The DREAM study was based on earlier evidence that
thiazolidinediones (TZD) and Angiotensin Converting
Enzyme Inhibitor (ACE-I) prevent diabetes.10,11 Ramipril,
an ACE-I was shown to prevent cardiovascular events
in high-risk people, including those with diabetes, in
the Heart Outcomes Prevention Evaluation (HOPE)
study.10 Secondary findings indicated that ramipril may
also prevent diabetes. The  Troglitazone in Prevention of
Diabetes [TRIPOD] study showed that troglitazone, the
first TZD introduced in the market could prevent
diabetes.11 Unfortunately this study was terminated as
troglitazone was with drawn from the market due to
liver toxicity. Rosiglitazone is another TZD currently
used to treat diabetes. Rosiglitazone activates peroxisome
proliferator-activated gamma receptors and increases
peripheral insulin sensitivity and thus decreases insulin
resistance.12
The aim of the DREAM study was to determine the
effect of ramipril and rosiglitazone in preventing
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diabetes in subjects with pre-diabetes [IGT or IFG]. The
study had four arms and the study participants were
provided with either or both the drugs or a placebo.
DREAM study recruited 5,269 people with pre-diabetes
from 191 clinics in 21 countries world-wide. McMaster
University, Hamilton, Ontario, Canada was the
coordinating centre for the study. Six Indian centres
participated and contributed  over 650 pre-diabetic
individuals to the trial. Results of the trial were recently
presented at the 42nd Annual Meeting of the European
Association for the Study of Diabetes at Copenhagen
and published online in the Lancet [Rosiglitazone arm]8
and the New England Journal of Medicine [Ramipril
arm].9
Beneficial effects of rosiglitazone in preventing
diabetes
Of the 2635 study subjects taking rosiglitazone, 280
[10.6%] developed diabetes compared to 658 out of 2634
[25.0%] in the placebo arm. The hazard ratio [HR] for
developing diabetes was 0.38 [95% confidence interval:
[CI ] [0.33 - 0.44] which mean diabetes was prevented by
62%. Additionally, rosialitazone promotes regression to
normoglycemia by 70% compared to placebo. Though
death rates were not significantly different in both the
study groups, it was slightly lower in the rosiglitazone
arm. Overall, 8 mg of rosiglitazone daily along with
lifestyle recommendations decreased the occurrence of
primary end-points which includes diabetes or death
by 60%.8
An interesting observation in the study was that the
diabetes risk reduction increased in those with greater
body weight. In other words, obese subjects benefited
the most. The hazard reduction for diabetes or death
was 40% in people with body mass index <28 kg/m2,
which increased to 68% in subjects with body mass
index:  >32 kg/m2. Similar results were observed with
regard to abdominal obesity defined based on waist
circumference. Despite increase in body weight and body
mass index, there was a significant decrease in waist to
hip ratio indicating redistribution of fat from the more
harmful central (abdominal) areas to the peripheral areas
(hip). The effect of rosiglitazone on the primary end-
points was beneficial irrespective of age, sex or ethnic
group. Though there was no significant difference in
the overall cardiovascular events between study groups,
the frequency of non-fatal heart failure was higher in
the rosiglitazone arm compared to the placebo group.
However, there were no serious episodes of cardiac
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failure in the trial. Yet another interesting observation
in the study was that rosiglitazone decreased serum ALT
levels, indicating that it is hepato-friendly, in contrast to
troglitazone.8
The diabetes prevention effect of rosiglitazone may
be due to its insulin sensitizing effect.12 However, it could
also be a glucose masking effect. After the wash-out
period, the sustainability of the effect of rosiglitazone
needs to be assessed further.
Effect of ramipril on prevention of diabetes and
regression to normal
In contrast to rosiglitazone, ramipril did not prevent
diabetes, as nearly 17.1% of participants on ramipril and
18.5% on placebo developed diabetes. However,
regression to normal in the ramipril arm was
significantly higher compared to the placebo arm [42.5%
vs 38.2%], HR:1.16 [95% CI:1.07-1.27]. As expected, blood
pressure decreased significantly in the ramipril arm
compared to placebo. Median levels of two hour post-
load plasma glucose levels, but not fasting plasma
glucose levels was significantly lower in the ramipril
compared to placebo [135.1 mg/dl vs 140.5 mg/dl,
p=0.01]. There was no difference in the cardiovascular
end points between the study arms.9
A metaanalysis on 12 trials using ACEIs revealed that
ACEIs had a beneficial effect in preventing diabetes.13,14
The DREAM study results are however, not in agreement
with this observation. This discrepancy could be due to
the following reasons: 1. earlier trials were not designed
to assess prevention of diabetes as the primary endpoint
unlike DREAM, leading to a possibility of ascertainment
bias; 2. unlike earlier trials, DREAM recruited study
subjects with pre-diabetes and not subjects with high
risk for cardiovascular disease like hypertension or
diabetes; 3. follow-up required for ramipril to exert its
effect may be longer than the study duration of DREAM
which was only three years.  Hence there is a possibility
that if the study was extended,  ramipril could have had
a modest beneficial effect in preventing diabetes.
In summary, the DREAM study very clearly
demonstrates that rosiglitazone which is already used
in treatment of diabetes, may significantly reduce the
chances of developing the disease when taken by those
at high risk such as those with pre diabetes. As pre-
diabetic subjects have an increased risk for
cardiovascular events, if we can prevent diabetes, the
occurrence of serious complications such as
cardiovascular disease and microvascular
complications of diabetes could also possibly be
prevented.
How do the study results impact India?
Recent studies within the Indian subcontinent show
that in urban India, prevalence rates of diabetes are fast
approaching those seen in more affluent migrant
Indians.15,16 The Chennai Urban Rural Epidemiology
Study [CURES] conducted on a representative
population of Chennai indicated a rising trend in
prevalence of diabetes. The overall crude prevalence of
diabetes in CURES is 15.5% [age standardized: 14.3%]
which includes 6.1% self-reported diabetes and 9.4%
previously undiagnosed diabetes. The prevalence of
diabetes in Chennai city increased by 39.8% from 1989
to 1995 [8.3% to 11.6%], by 16.3% in the next five years
[11.6% to 13.5%], and by 6.0% in the subsequent four
years [13.5% to 14.3%]. Thus, within a span of 15 years,
the prevalence of diabetes in Chennai increased by
72.3%.17 It is likely that similar increases occur in other
urban areas also.
Prevalence of IGT in the CURES study was 10.2%.
The age-standardized prevalence of IGT increased by
9.6% from 1989 to 1995 [8.3% to 9.1%] and by 84.6%
between 1995 and 2000 [9.1% to 16.8%]. However, it
decreased by 39.3% between 2000 to 2004.17 The decrease
in prevalence of IGT is of importance as this could reflect
rapid progression from normal through IGT to diabetes,
leading to drastic increase in prevalence of diabetes due
to a worsening diabetogenic environment. These
observations clearly emphasize the need for preventive
measures to reduce the health burden due to diabetes. It
is very likely that a similar scenario exists for other parts
of India although no secular trends are available.
The PODIS study18 showed that 5.2% of adults aged
≥ 20 had pre-diabetes in India which translates to
approximately 30 million individuals with pre diabetes.
If no intervention is done, in five years, the number of
pre-diabetic adults who will get converted to diabetes
would be approximately 10 million. This will
substantially increase the number of people with
diabetes in India. If we add pharmacotherapy viz.
rosiglitazone to lifestyle recommendations, nearly 5
million people will be prevented from developing
diabetes.
So should we start prescribing drugs to prevent
diabetes and cardiovascular disease in pre-diabetic
individuals? Obviously lifestyle modification still
remains the first step as it is the healthiest and most
cost- effective intervention measure. However, if this does
not work, or for very high risk subjects,
pharmacotherapy using rosiglitazone may be an option.
While ramipril cannot be recommended for prevention
of diabetes, the fact that it lowers plasma glucose levels
favourably and its cardiovascular benefits encourages
advising the drug for pre-diabetic subjects with
hypertension, microalbuminuria or high cardiovascular
risk.
There are still several unanswered questions: will
rosiglitazone be able to sustain its effect if the drug is
withdrawn? What will be the cost effectiveness of using
rosiglitazone for prolonged periods of time? Future
studies need to address these issues.
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